Correspondence  by unknown
finding raises a red flag in my mind, suggesting the need for
further research, especially for women at risk of breast
cancer who are considered for or are already taking HMG-
CoA-reductase inhibitors for cholesterol-lowering. We owe
it to our patients to look further into this issue before we
routinely prescribe what has the potential to be a dangerous
medication for some women.
Stephen T. Sinatra, MD, FACC
Eastern Connecticut Health Network
University School of Medicine
Farmington, Connecticut
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REPLY
We looked very carefully into reasons for the difference in
the number of breast cancer cases between the pravastatin
and placebo groups in the CARE trial (1), and concluded
that it was a statistical aberration related to an unexpectedly
low incidence of new breast cancers in the placebo group.
There was not a single case of new invasive breast cancer
reported in the 290 women in the placebo group during the
five years of the trial; the one reported case was a metastasis
of a previously treated cancer. On the basis of epidemiolog-
ical data in the U.S. and Canada where the trial was
conducted, five cases of new invasive breast cancer were
expected (95% confidence interval, 0.6 to 9.3). In contrast,
the number of new invasive breast cancer cases in the
pravastatin group, eight, was closer to the expected number
of five, and within its confidence interval. These findings
strongly suggested that the imbalance in breast cancer
incidence between the treatment groups was linked to
chance rather than a biologic effect of pravastatin. This
conclusion was further supported by the findings from the
LIPID trial (2), which included more than 2.5 times as
many women as CARE, and had a longer median follow-up
(5.9 vs. 4.9 years). In LIPID, no differences were observed
between placebo and pravastatin-treated groups in the
incidence of breast cancer, with 10 reports in each group (2).
Findings were similar for long-term trials using other
HMG CoA reductase inhibitors (3,4).
One would have expected, if the coenzyme Q10 hypoth-
esis proposed by Dr. Sinatra was true, that increases in
incidence of other types of cancer would have been observed
with statin treatment. In fact, total cancer incidence was
similar in the drug and placebo groups not only in CARE,
but in all of the long-term statin trials, totaling over 30,000
patients (2–6).
Finally, there is no evidence that pravastatin produced
sustained decreases in plasma coenzyme Q10. In a study in
patients with hypercholesterolemia, pravastatin 40–80 mg
daily reduced coenzyme Q10 levels by 16 to 24% after four
and eight weeks of treatment, but levels returned to normal
by 20 weeks (12% above baseline) and remained normal
through to 56 weeks of treatment (13% above baseline).
The CARE trial showed that the benefits of pravastatin
treatment for women with coronary disease are substantial,
a 46% reduction in recurrent coronary events and a 56%
reduction in stroke. The lack of established risk of cancer or
other noncardiovascular morbidity clearly favors treating our
female coronary patients, a population in whom cardiovas-
cular disease is typically under-treated, despite being the
leading cause of death.
Frank M. Sacks, MD
Harvard School of Public Health and
Harvard Medical School
Boston, Massachusetts
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Aortic Atheromas and Historical Justice
We read with great interest the article by Dressler et al. (1)
dealing with the efficacy of anticoagulation and influence of
plaque morphology on recurrent stroke. Their findings are
in keeping with those of a recent report from our laboratory
stressing the importance of disrupted aortic plaques as a
major risk factor for systemic embolism in the elderly (2).
Moreover, the suggestion that anticoagulation should be the
treatment of choice in patients with mobile aortic athero-
mas—even in those with small mobile components—
represents a valuable contribution in the yet controversial
therapeutic approach to this challenging clinical problem.
We would like to bring to the authors’ attention two
points. First is an oversight in the Results section. When
describing the follow-up events of patients with atheroma,
readers are referred to Table 2, but this table deals only with
plaque dimensions (repeating data given in the text). The
next paragraph analyzes the influence of anticoagulation on
recurrent stroke in the three morphologic groups, and
readers are referred to Table 3, which actually deals with
follow-up events. We believe that these errors are probably
derived from a misprint that omitted the “true” Table 3,
data that would be interesting to see.
Second, it is stated at the beginning of the article that
“nearly 40 years have passed since the aorta was first
recognized as a source for systemic emboli,” quoting the
description by Winter of cerebral infarction caused by
atheromatous emboli (3). In fact, the entity had already
been described in the last century; experimental emboliza-
tion from aortic source was reported as early as in 1862 (4).
In addition, autopsy evidence of arterial occlusions by emboli
from eroded aortic atheromatous plaques was published in
1945 (5), twelve years before Winter’s communication. Today,
when the role of aortic atheromas in systemic emboli seems to
be obvious, historical justice requires that the pioneering works
of Panum and Flory should not be forgotten.
Enrique Z. Fisman, MD
Alexander Tenenbaum, MD, PhD
Cardiac Rehabilitation Institute
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The Malpractice Crisis and
the “Expert” Witness:
The Problem and a Proposed Solution
Malpractice litigation in the U.S. has reached crisis. Premi-
ums for malpractice insurance are often astronomical, in
some cases forcing physicians out of practice, and the fear of
legal attack, often unjustified and even frivoulous, dogs
every practitioner. The entire structure of malpractice liti-
gation rests on expert testimony. Without expert testimony,
no malpractice action could ever succeed, and it comes as a
shock to realize that the malpractice crisis in the U.S. is only
made possible by certain physicians offering expert testi-
mony for large fees on either side of any case. These
individuals actually advertise their wares in legal journals,
sometimes as corporations of professional witnesses.
Knowledgeable attorneys are completely cynical about these
individuals: They know that they can hire a physician to
testify to “anything, absolutely anything”—to quote one of
the leading trial lawyers in the U.S.
There are remedies. Under British law, a witness, expert
or not, cannot be paid for testimony. Any evidence of
payment excludes the witness. (Under British law there are
no contingent fees for counsel, another wholesome provi-
sion.) My personal response is simple but effective and may
serve as a paradigm for the country. I offer my services, free
of charge, for any case within my competence. I review the
file, advise counsel and appear to testify if necessary. I am
careful to explain that I do this as a public service, with no
question of remuneration, as an obligation I feel I owe my
profession and the public. If there is evidence of gross
incompetence, I advise counsel to settle. If I see perjured
expert testimony, I am glad to take the stand to describe it
as such. This is well and good as far as it goes, but after some
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